Global Pyelonephritis Market

Pyelonephritis Comprehensive Study by Type (Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate), Application (Hospitals, Clinics), Treatement (Antibiotics, Hospital Admission, Surgery) Players and Region - Global Market Outlook to 2029

Pyelonephritis Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Pyelonephritis is a type of urinary tract infection (UTI) that affects one or both kidneys. Pyelonephritis is caused by a bacterium or virus infecting the kidneys. Though many bacteria and viruses can cause pyelonephritis. Bacteria and viruses can move to the kidneys from the bladder or can be carried through the bloodstream from other parts of the body. People most at risk for pyelonephritis are those who have a bladder infection and those with a structural, or anatomic, problem in the urinary tract.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)


Market Drivers
  • Growing kidney related diseases (such as kidney stones and bladder conditions)

Market Trend
  • Increase demand for treatment of pyelonephritis

Restraints
  • Availability of substitute drug in the market

Opportunities
Increasing investment in healthcare sector by the government in emerging countries

Pyelonephritis Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals and Clinics
TypeFinafloxacin, Fosfomycin Tromethamine, Nacubactam and Plazomicin Sulfate
TreatementAntibiotics,Hospital Admission,Surgery


Players Covered in the Study are:
Achaogen Inc. (United States), AstraZeneca Plc (United Kingdom), Meiji Seika Pharma Co Ltd (Japan), Merck & Co Inc. (United States), MerLion Pharmaceuticals Pte Ltd. (Singapore), The Medicines Company (United States) and Zavante Therapeutics Inc. (United States)

The Global Pyelonephritis market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Industry Insights:
In July 2019 , Cipla USA Inc. a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited hereafter referred to as "Cipla"), announced the acquisition of the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. ("Achaogen") in a Chapter 11, U.S. Bankruptcy Code auction of Achaogen's assets. Cipla USA has acquired worldwide rights of ZEMDRI™ (excluding Greater China) with its allied assets and limited liabilities.
In Sept. 2023 , Everest Medicines a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines in Greater China and other parts of Asia, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for cefepime-taniborbactam for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, based on the criteria of "innovative drugs for the prevention and treatment of major infectious diseases and rare diseases that meet urgent clinical needs."


Key Target Audience
Manufacturer of Pyelonephritis Drug, Supplier of Pyelonephritis Drug, Wholesalers, Distributers and Retailers of Pyelonephritis Drug, Healthcare Industry and Research Firms

What can be explored with Pyelonephritis study:
• Where Pyelonephritis industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are TEVA Pharmaceutical Industries LTD (Israel), Zhejiang Medicine Co., Ltd. (China) and Sun Pharmaceutical Industries Ltd. (India).


Report Objectives / Segmentation Covered

By Type
  • Finafloxacin
  • Fosfomycin Tromethamine
  • Nacubactam
  • Plazomicin Sulfate
By Application
  • Hospitals
  • Clinics
By Treatement
  • Antibiotics
  • Hospital Admission
  • Surgery

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing kidney related diseases (such as kidney stones and bladder conditions)
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about the treatment for pyelonephritis
    • 3.4. Market Trends
      • 3.4.1. Increase demand for treatment of pyelonephritis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pyelonephritis, by Type, Application, Treatement and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pyelonephritis (Value)
      • 5.2.1. Global Pyelonephritis by: Type (Value)
        • 5.2.1.1. Finafloxacin
        • 5.2.1.2. Fosfomycin Tromethamine
        • 5.2.1.3. Nacubactam
        • 5.2.1.4. Plazomicin Sulfate
      • 5.2.2. Global Pyelonephritis by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Pyelonephritis by: Treatement (Value)
        • 5.2.3.1. Antibiotics
        • 5.2.3.2. Hospital Admission
        • 5.2.3.3. Surgery
      • 5.2.4. Global Pyelonephritis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pyelonephritis (Price)
      • 5.3.1. Global Pyelonephritis by: Type (Price)
  • 6. Pyelonephritis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Achaogen Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Meiji Seika Pharma Co Ltd (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MerLion Pharmaceuticals Pte Ltd. (Singapore)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. The Medicines Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zavante Therapeutics Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Pyelonephritis Sale, by Type, Application, Treatement and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Pyelonephritis (Value)
      • 7.2.1. Global Pyelonephritis by: Type (Value)
        • 7.2.1.1. Finafloxacin
        • 7.2.1.2. Fosfomycin Tromethamine
        • 7.2.1.3. Nacubactam
        • 7.2.1.4. Plazomicin Sulfate
      • 7.2.2. Global Pyelonephritis by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Pyelonephritis by: Treatement (Value)
        • 7.2.3.1. Antibiotics
        • 7.2.3.2. Hospital Admission
        • 7.2.3.3. Surgery
      • 7.2.4. Global Pyelonephritis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pyelonephritis (Price)
      • 7.3.1. Global Pyelonephritis by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pyelonephritis: by Type(USD Million)
  • Table 2. Pyelonephritis Finafloxacin , by Region USD Million (2018-2023)
  • Table 3. Pyelonephritis Fosfomycin Tromethamine , by Region USD Million (2018-2023)
  • Table 4. Pyelonephritis Nacubactam , by Region USD Million (2018-2023)
  • Table 5. Pyelonephritis Plazomicin Sulfate , by Region USD Million (2018-2023)
  • Table 6. Pyelonephritis: by Application(USD Million)
  • Table 7. Pyelonephritis Hospitals , by Region USD Million (2018-2023)
  • Table 8. Pyelonephritis Clinics , by Region USD Million (2018-2023)
  • Table 9. Pyelonephritis: by Treatement(USD Million)
  • Table 10. Pyelonephritis Antibiotics , by Region USD Million (2018-2023)
  • Table 11. Pyelonephritis Hospital Admission , by Region USD Million (2018-2023)
  • Table 12. Pyelonephritis Surgery , by Region USD Million (2018-2023)
  • Table 13. South America Pyelonephritis, by Country USD Million (2018-2023)
  • Table 14. South America Pyelonephritis, by Type USD Million (2018-2023)
  • Table 15. South America Pyelonephritis, by Application USD Million (2018-2023)
  • Table 16. South America Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 17. Brazil Pyelonephritis, by Type USD Million (2018-2023)
  • Table 18. Brazil Pyelonephritis, by Application USD Million (2018-2023)
  • Table 19. Brazil Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 20. Argentina Pyelonephritis, by Type USD Million (2018-2023)
  • Table 21. Argentina Pyelonephritis, by Application USD Million (2018-2023)
  • Table 22. Argentina Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 23. Rest of South America Pyelonephritis, by Type USD Million (2018-2023)
  • Table 24. Rest of South America Pyelonephritis, by Application USD Million (2018-2023)
  • Table 25. Rest of South America Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 26. Asia Pacific Pyelonephritis, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Pyelonephritis, by Type USD Million (2018-2023)
  • Table 28. Asia Pacific Pyelonephritis, by Application USD Million (2018-2023)
  • Table 29. Asia Pacific Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 30. China Pyelonephritis, by Type USD Million (2018-2023)
  • Table 31. China Pyelonephritis, by Application USD Million (2018-2023)
  • Table 32. China Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 33. Japan Pyelonephritis, by Type USD Million (2018-2023)
  • Table 34. Japan Pyelonephritis, by Application USD Million (2018-2023)
  • Table 35. Japan Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 36. India Pyelonephritis, by Type USD Million (2018-2023)
  • Table 37. India Pyelonephritis, by Application USD Million (2018-2023)
  • Table 38. India Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 39. South Korea Pyelonephritis, by Type USD Million (2018-2023)
  • Table 40. South Korea Pyelonephritis, by Application USD Million (2018-2023)
  • Table 41. South Korea Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 42. Taiwan Pyelonephritis, by Type USD Million (2018-2023)
  • Table 43. Taiwan Pyelonephritis, by Application USD Million (2018-2023)
  • Table 44. Taiwan Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 45. Australia Pyelonephritis, by Type USD Million (2018-2023)
  • Table 46. Australia Pyelonephritis, by Application USD Million (2018-2023)
  • Table 47. Australia Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Pyelonephritis, by Type USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Pyelonephritis, by Application USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 51. Europe Pyelonephritis, by Country USD Million (2018-2023)
  • Table 52. Europe Pyelonephritis, by Type USD Million (2018-2023)
  • Table 53. Europe Pyelonephritis, by Application USD Million (2018-2023)
  • Table 54. Europe Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 55. Germany Pyelonephritis, by Type USD Million (2018-2023)
  • Table 56. Germany Pyelonephritis, by Application USD Million (2018-2023)
  • Table 57. Germany Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 58. France Pyelonephritis, by Type USD Million (2018-2023)
  • Table 59. France Pyelonephritis, by Application USD Million (2018-2023)
  • Table 60. France Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 61. Italy Pyelonephritis, by Type USD Million (2018-2023)
  • Table 62. Italy Pyelonephritis, by Application USD Million (2018-2023)
  • Table 63. Italy Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 64. United Kingdom Pyelonephritis, by Type USD Million (2018-2023)
  • Table 65. United Kingdom Pyelonephritis, by Application USD Million (2018-2023)
  • Table 66. United Kingdom Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 67. Netherlands Pyelonephritis, by Type USD Million (2018-2023)
  • Table 68. Netherlands Pyelonephritis, by Application USD Million (2018-2023)
  • Table 69. Netherlands Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 70. Rest of Europe Pyelonephritis, by Type USD Million (2018-2023)
  • Table 71. Rest of Europe Pyelonephritis, by Application USD Million (2018-2023)
  • Table 72. Rest of Europe Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 73. MEA Pyelonephritis, by Country USD Million (2018-2023)
  • Table 74. MEA Pyelonephritis, by Type USD Million (2018-2023)
  • Table 75. MEA Pyelonephritis, by Application USD Million (2018-2023)
  • Table 76. MEA Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 77. Middle East Pyelonephritis, by Type USD Million (2018-2023)
  • Table 78. Middle East Pyelonephritis, by Application USD Million (2018-2023)
  • Table 79. Middle East Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 80. Africa Pyelonephritis, by Type USD Million (2018-2023)
  • Table 81. Africa Pyelonephritis, by Application USD Million (2018-2023)
  • Table 82. Africa Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 83. North America Pyelonephritis, by Country USD Million (2018-2023)
  • Table 84. North America Pyelonephritis, by Type USD Million (2018-2023)
  • Table 85. North America Pyelonephritis, by Application USD Million (2018-2023)
  • Table 86. North America Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 87. United States Pyelonephritis, by Type USD Million (2018-2023)
  • Table 88. United States Pyelonephritis, by Application USD Million (2018-2023)
  • Table 89. United States Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 90. Canada Pyelonephritis, by Type USD Million (2018-2023)
  • Table 91. Canada Pyelonephritis, by Application USD Million (2018-2023)
  • Table 92. Canada Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 93. Mexico Pyelonephritis, by Type USD Million (2018-2023)
  • Table 94. Mexico Pyelonephritis, by Application USD Million (2018-2023)
  • Table 95. Mexico Pyelonephritis, by Treatement USD Million (2018-2023)
  • Table 96. Pyelonephritis: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Pyelonephritis: by Type(USD Million)
  • Table 105. Pyelonephritis Finafloxacin , by Region USD Million (2024-2029)
  • Table 106. Pyelonephritis Fosfomycin Tromethamine , by Region USD Million (2024-2029)
  • Table 107. Pyelonephritis Nacubactam , by Region USD Million (2024-2029)
  • Table 108. Pyelonephritis Plazomicin Sulfate , by Region USD Million (2024-2029)
  • Table 109. Pyelonephritis: by Application(USD Million)
  • Table 110. Pyelonephritis Hospitals , by Region USD Million (2024-2029)
  • Table 111. Pyelonephritis Clinics , by Region USD Million (2024-2029)
  • Table 112. Pyelonephritis: by Treatement(USD Million)
  • Table 113. Pyelonephritis Antibiotics , by Region USD Million (2024-2029)
  • Table 114. Pyelonephritis Hospital Admission , by Region USD Million (2024-2029)
  • Table 115. Pyelonephritis Surgery , by Region USD Million (2024-2029)
  • Table 116. South America Pyelonephritis, by Country USD Million (2024-2029)
  • Table 117. South America Pyelonephritis, by Type USD Million (2024-2029)
  • Table 118. South America Pyelonephritis, by Application USD Million (2024-2029)
  • Table 119. South America Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 120. Brazil Pyelonephritis, by Type USD Million (2024-2029)
  • Table 121. Brazil Pyelonephritis, by Application USD Million (2024-2029)
  • Table 122. Brazil Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 123. Argentina Pyelonephritis, by Type USD Million (2024-2029)
  • Table 124. Argentina Pyelonephritis, by Application USD Million (2024-2029)
  • Table 125. Argentina Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 126. Rest of South America Pyelonephritis, by Type USD Million (2024-2029)
  • Table 127. Rest of South America Pyelonephritis, by Application USD Million (2024-2029)
  • Table 128. Rest of South America Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 129. Asia Pacific Pyelonephritis, by Country USD Million (2024-2029)
  • Table 130. Asia Pacific Pyelonephritis, by Type USD Million (2024-2029)
  • Table 131. Asia Pacific Pyelonephritis, by Application USD Million (2024-2029)
  • Table 132. Asia Pacific Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 133. China Pyelonephritis, by Type USD Million (2024-2029)
  • Table 134. China Pyelonephritis, by Application USD Million (2024-2029)
  • Table 135. China Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 136. Japan Pyelonephritis, by Type USD Million (2024-2029)
  • Table 137. Japan Pyelonephritis, by Application USD Million (2024-2029)
  • Table 138. Japan Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 139. India Pyelonephritis, by Type USD Million (2024-2029)
  • Table 140. India Pyelonephritis, by Application USD Million (2024-2029)
  • Table 141. India Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 142. South Korea Pyelonephritis, by Type USD Million (2024-2029)
  • Table 143. South Korea Pyelonephritis, by Application USD Million (2024-2029)
  • Table 144. South Korea Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 145. Taiwan Pyelonephritis, by Type USD Million (2024-2029)
  • Table 146. Taiwan Pyelonephritis, by Application USD Million (2024-2029)
  • Table 147. Taiwan Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 148. Australia Pyelonephritis, by Type USD Million (2024-2029)
  • Table 149. Australia Pyelonephritis, by Application USD Million (2024-2029)
  • Table 150. Australia Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 151. Rest of Asia-Pacific Pyelonephritis, by Type USD Million (2024-2029)
  • Table 152. Rest of Asia-Pacific Pyelonephritis, by Application USD Million (2024-2029)
  • Table 153. Rest of Asia-Pacific Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 154. Europe Pyelonephritis, by Country USD Million (2024-2029)
  • Table 155. Europe Pyelonephritis, by Type USD Million (2024-2029)
  • Table 156. Europe Pyelonephritis, by Application USD Million (2024-2029)
  • Table 157. Europe Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 158. Germany Pyelonephritis, by Type USD Million (2024-2029)
  • Table 159. Germany Pyelonephritis, by Application USD Million (2024-2029)
  • Table 160. Germany Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 161. France Pyelonephritis, by Type USD Million (2024-2029)
  • Table 162. France Pyelonephritis, by Application USD Million (2024-2029)
  • Table 163. France Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 164. Italy Pyelonephritis, by Type USD Million (2024-2029)
  • Table 165. Italy Pyelonephritis, by Application USD Million (2024-2029)
  • Table 166. Italy Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 167. United Kingdom Pyelonephritis, by Type USD Million (2024-2029)
  • Table 168. United Kingdom Pyelonephritis, by Application USD Million (2024-2029)
  • Table 169. United Kingdom Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 170. Netherlands Pyelonephritis, by Type USD Million (2024-2029)
  • Table 171. Netherlands Pyelonephritis, by Application USD Million (2024-2029)
  • Table 172. Netherlands Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 173. Rest of Europe Pyelonephritis, by Type USD Million (2024-2029)
  • Table 174. Rest of Europe Pyelonephritis, by Application USD Million (2024-2029)
  • Table 175. Rest of Europe Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 176. MEA Pyelonephritis, by Country USD Million (2024-2029)
  • Table 177. MEA Pyelonephritis, by Type USD Million (2024-2029)
  • Table 178. MEA Pyelonephritis, by Application USD Million (2024-2029)
  • Table 179. MEA Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 180. Middle East Pyelonephritis, by Type USD Million (2024-2029)
  • Table 181. Middle East Pyelonephritis, by Application USD Million (2024-2029)
  • Table 182. Middle East Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 183. Africa Pyelonephritis, by Type USD Million (2024-2029)
  • Table 184. Africa Pyelonephritis, by Application USD Million (2024-2029)
  • Table 185. Africa Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 186. North America Pyelonephritis, by Country USD Million (2024-2029)
  • Table 187. North America Pyelonephritis, by Type USD Million (2024-2029)
  • Table 188. North America Pyelonephritis, by Application USD Million (2024-2029)
  • Table 189. North America Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 190. United States Pyelonephritis, by Type USD Million (2024-2029)
  • Table 191. United States Pyelonephritis, by Application USD Million (2024-2029)
  • Table 192. United States Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 193. Canada Pyelonephritis, by Type USD Million (2024-2029)
  • Table 194. Canada Pyelonephritis, by Application USD Million (2024-2029)
  • Table 195. Canada Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 196. Mexico Pyelonephritis, by Type USD Million (2024-2029)
  • Table 197. Mexico Pyelonephritis, by Application USD Million (2024-2029)
  • Table 198. Mexico Pyelonephritis, by Treatement USD Million (2024-2029)
  • Table 199. Pyelonephritis: by Type(USD/Units)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pyelonephritis: by Type USD Million (2018-2023)
  • Figure 5. Global Pyelonephritis: by Application USD Million (2018-2023)
  • Figure 6. Global Pyelonephritis: by Treatement USD Million (2018-2023)
  • Figure 7. South America Pyelonephritis Share (%), by Country
  • Figure 8. Asia Pacific Pyelonephritis Share (%), by Country
  • Figure 9. Europe Pyelonephritis Share (%), by Country
  • Figure 10. MEA Pyelonephritis Share (%), by Country
  • Figure 11. North America Pyelonephritis Share (%), by Country
  • Figure 12. Global Pyelonephritis: by Type USD/Units (2018-2023)
  • Figure 13. Global Pyelonephritis share by Players 2023 (%)
  • Figure 14. Global Pyelonephritis share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Achaogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Achaogen Inc. (United States) Revenue: by Geography 2023
  • Figure 18. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Meiji Seika Pharma Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Meiji Seika Pharma Co Ltd (Japan) Revenue: by Geography 2023
  • Figure 22. Merck & Co Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co Inc. (United States) Revenue: by Geography 2023
  • Figure 24. MerLion Pharmaceuticals Pte Ltd. (Singapore) Revenue, Net Income and Gross profit
  • Figure 25. MerLion Pharmaceuticals Pte Ltd. (Singapore) Revenue: by Geography 2023
  • Figure 26. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. The Medicines Company (United States) Revenue: by Geography 2023
  • Figure 28. Zavante Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Zavante Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Global Pyelonephritis: by Type USD Million (2024-2029)
  • Figure 31. Global Pyelonephritis: by Application USD Million (2024-2029)
  • Figure 32. Global Pyelonephritis: by Treatement USD Million (2024-2029)
  • Figure 33. South America Pyelonephritis Share (%), by Country
  • Figure 34. Asia Pacific Pyelonephritis Share (%), by Country
  • Figure 35. Europe Pyelonephritis Share (%), by Country
  • Figure 36. MEA Pyelonephritis Share (%), by Country
  • Figure 37. North America Pyelonephritis Share (%), by Country
  • Figure 38. Global Pyelonephritis: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Achaogen Inc. (United States)
  • AstraZeneca Plc (United Kingdom)
  • Meiji Seika Pharma Co Ltd (Japan)
  • Merck & Co Inc. (United States)
  • MerLion Pharmaceuticals Pte Ltd. (Singapore)
  • The Medicines Company (United States)
  • Zavante Therapeutics Inc. (United States)
Additional players considered in the study are as follows:
TEVA Pharmaceutical Industries LTD (Israel) , Zhejiang Medicine Co., Ltd. (China) , Sun Pharmaceutical Industries Ltd. (India)
Select User Access Type

Key Highlights of Report


Jan 2024 203 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pyelonephritis Market Quantitative research analysis
Global Pyelonephritis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Hospitals and Clinics are major end use applications of Pyelonephritis market.
Top performing companies in the Global Pyelonephritis market are Achaogen Inc. (United States), AstraZeneca Plc (United Kingdom), Meiji Seika Pharma Co Ltd (Japan), Merck & Co Inc. (United States), MerLion Pharmaceuticals Pte Ltd. (Singapore), The Medicines Company (United States) and Zavante Therapeutics Inc. (United States), to name a few.
The Concentration Rate of Global Pyelonephritis market is highlighted using HHI Index.
"Increase demand for treatment of pyelonephritis" is seen as one of major influencing trends for Pyelonephritis Market during projected period 2023-2029.
The Pyelonephritis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pyelonephritis Market Report?

Have a Query? Click Here

Other Related Reports

Cerebral Palsy Treatment Comprehensive Study by Type (Medications (Musel or Nerve Injections and Oral Muscle Relaxants), Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy...
$ 3750
Premature Ejaculation Comprehensive Study by Type (Lifelong (Primary), Acquired (Secondary)), Application (Hospitals, Clinics), Treatment (Medical Therapy, Non-Medical Therapy) Players and Region - G...
$ 3500
Lyme Disease Diagnostics Comprehensive Study by Diagnostic Technology (Serological Test (ELISA, Western Blot), Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nuclei...
$ 3450
Psoriatic Arthritis Treatment Comprehensive Study by Treatment (Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others), Surgical Procedur...
$ 3750
Gene expression analysis Comprehensive Study by Type (Consumables (Reagents, DNA Chips), Instruments (PCR, NGS, Microarray)), Application (Diagnostics, Pharmacogenomics, Toxicology, Compare Expressio...
$ 3750
Edible Vaccines Comprehensive Study by Type (Inactivated Vaccines, Others), Application (Medical Care, Livestock, Others) Players and Region - Global Market Outlook to 2030
$ 3500